FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017023812> ?p ?o ?g. }

• W2017023812 endingPage "59" @default.
• W2017023812 startingPage "56" @default.
• W2017023812 abstract "The prognostic models in Hodgkin lymphoma (HL) such as the International Prognostic Score (IPS), retrospectively constructed in the last twenty years from different cohorts of patients treated with ABVD or ABVD-equivalent regimens have been shown a limited predictive value on treatment outcome when applied to a prospective cohort of patients. In the turn of millennium a new class of prognostic factors has emerged, aimed to test the chemosensitivity to treatment in a single patient-basis, such as the minimal residual disease (MRD) assessment with molecular biology, or interim PET/CT performed early during treatment. The main challenge in the management of both early and advanced-stage HL is to achieve a durable remission or cure while minimizing therapy toxicity. An adaptive therapy strategy based on interim PET results could distinguish high from low-risk patients: the former with a potential benefit from an intensify regimen, the latter in whom treatment could be de-escalated or abbreviated for minimizing long-term adverse effects. Conversely, chemosensitivity evaluation in early-stage HL has been the underpinning of de-escalation trials aimed at assessing the safety and the efficacy of omitting radiotherapy in interim PET-negative patients. Brentuximab Vedotin (BV) is a novel antibody–drug conjugate targeting CD30 linked to a potent synthetic antitubulin chemotherapeutic agent, monomethyl auristatin E (MME). BV showed an impressive activity against refractory/relapsed HL and now is being incorporated in a modified ABVD schedule in first-line treatment of HL, with promising efficacy and a low toxicity profile. This novel therapeutic strategy will tell us if traditional ABVD or BEACOPP chemotherapy could be abandoned for the brand-new targeted therapy. Despite the brilliant results of HL treatment, which proved able to achieve a long-term disease control in 80–90% of the patients, the search of new prognostic has continued over the last two decades and the progress of the knowledge of the pathobiology of HL has led to a discovery of a series of markers related to microenvironment of HL tissue and molecular mechanisms to escape host immune reaction against the tumor. The strong association between the locus A of the human leukocyte antigen (HLA-A) system and EBV-positive HL suggests that both an abnormal antigen presentation and some specific EBV antigen per se could play a pivotal role in the pathogenesis of cHL. In EBV + HL patients, the susceptibility or the resistance to develop HL depends on the HLA allele A-*01 or A-*02, respectively. Tumor escape mechanism to block the immune response of the host against the neoplastic tissue is one of the property of a recently discovered subset of myeloid-derived suppressor cells (MDSC) that induce tumor vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, MDSC derive from multipotent progenitor cells that can differentiate in the tissue as monocyte-derived MDSC (Mo-MDSC) with a phenotype CD14+/dull and granulocyte-derived MDSC (G-MDSC) expressing CD15 on cell surface. The latter were shown to produce arginase. Recent investigations suggest that MDSC present in the bone marrow in patients with several solid and hematological cancers in response to chemokine release in the tumor site are correlated with tumor-associated macrophages (TAM). Both TAM and MDSC have been strongly associated with a significantly worse prognosis in HL. As a consequence, several efforts are ongoing to standardize the methods to assess TAM and MDSC and prospective studies are being planned to validate their prognostic role." @default.
• W2017023812 created "2016-06-24" @default.
• W2017023812 creator A5004543040 @default.
• W2017023812 creator A5015840872 @default.
• W2017023812 creator A5018769545 @default.
• W2017023812 creator A5049532940 @default.
• W2017023812 creator A5062765629 @default.
• W2017023812 creator A5086227784 @default.
• W2017023812 date "2013-09-01" @default.
• W2017023812 modified "2023-10-18" @default.
• W2017023812 title "Standard therapies versus novel therapies in Hodgkin lymphoma" @default.
• W2017023812 cites W1495792176 @default.
• W2017023812 cites W1504115866 @default.
• W2017023812 cites W1976390651 @default.
• W2017023812 cites W1982673084 @default.
• W2017023812 cites W1988209525 @default.
• W2017023812 cites W1992908727 @default.
• W2017023812 cites W1993349395 @default.
• W2017023812 cites W2001292073 @default.
• W2017023812 cites W2003939651 @default.
• W2017023812 cites W2010746974 @default.
• W2017023812 cites W2014663568 @default.
• W2017023812 cites W2031456900 @default.
• W2017023812 cites W2034400622 @default.
• W2017023812 cites W2039970555 @default.
• W2017023812 cites W2054203685 @default.
• W2017023812 cites W2060001883 @default.
• W2017023812 cites W2060672294 @default.
• W2017023812 cites W2066799536 @default.
• W2017023812 cites W2068353573 @default.
• W2017023812 cites W2078346532 @default.
• W2017023812 cites W2083514525 @default.
• W2017023812 cites W2084579140 @default.
• W2017023812 cites W2085143233 @default.
• W2017023812 cites W2094798767 @default.
• W2017023812 cites W2104041191 @default.
• W2017023812 cites W2105936879 @default.
• W2017023812 cites W2108969608 @default.
• W2017023812 cites W2118169390 @default.
• W2017023812 cites W2120470395 @default.
• W2017023812 cites W2123026782 @default.
• W2017023812 cites W2133260927 @default.
• W2017023812 cites W2137965731 @default.
• W2017023812 cites W2141194628 @default.
• W2017023812 cites W2144769790 @default.
• W2017023812 cites W2147203767 @default.
• W2017023812 cites W2148788579 @default.
• W2017023812 cites W2156755241 @default.
• W2017023812 cites W2162084836 @default.
• W2017023812 cites W2162340856 @default.
• W2017023812 cites W2171775292 @default.
• W2017023812 cites W2328676772 @default.
• W2017023812 cites W2329725057 @default.
• W2017023812 cites W4239172580 @default.
• W2017023812 doi "https://doi.org/10.1016/j.imlet.2013.09.011" @default.
• W2017023812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24140162" @default.
• W2017023812 hasPublicationYear "2013" @default.
• W2017023812 type Work @default.
• W2017023812 sameAs 2017023812 @default.
• W2017023812 citedByCount "9" @default.
• W2017023812 countsByYear W20170238122014 @default.
• W2017023812 countsByYear W20170238122015 @default.
• W2017023812 countsByYear W20170238122018 @default.
• W2017023812 countsByYear W20170238122019 @default.
• W2017023812 countsByYear W20170238122020 @default.
• W2017023812 crossrefType "journal-article" @default.
• W2017023812 hasAuthorship W2017023812A5004543040 @default.
• W2017023812 hasAuthorship W2017023812A5015840872 @default.
• W2017023812 hasAuthorship W2017023812A5018769545 @default.
• W2017023812 hasAuthorship W2017023812A5049532940 @default.
• W2017023812 hasAuthorship W2017023812A5062765629 @default.
• W2017023812 hasAuthorship W2017023812A5086227784 @default.
• W2017023812 hasConcept C126322002 @default.
• W2017023812 hasConcept C143998085 @default.
• W2017023812 hasConcept C2776305933 @default.
• W2017023812 hasConcept C2776694085 @default.
• W2017023812 hasConcept C2776755627 @default.
• W2017023812 hasConcept C2778191690 @default.
• W2017023812 hasConcept C2779338263 @default.
• W2017023812 hasConcept C2779429289 @default.
• W2017023812 hasConcept C2781413609 @default.
• W2017023812 hasConcept C535046627 @default.
• W2017023812 hasConcept C61943457 @default.
• W2017023812 hasConcept C70905583 @default.
• W2017023812 hasConcept C71924100 @default.
• W2017023812 hasConceptScore W2017023812C126322002 @default.
• W2017023812 hasConceptScore W2017023812C143998085 @default.
• W2017023812 hasConceptScore W2017023812C2776305933 @default.
• W2017023812 hasConceptScore W2017023812C2776694085 @default.
• W2017023812 hasConceptScore W2017023812C2776755627 @default.
• W2017023812 hasConceptScore W2017023812C2778191690 @default.
• W2017023812 hasConceptScore W2017023812C2779338263 @default.
• W2017023812 hasConceptScore W2017023812C2779429289 @default.
• W2017023812 hasConceptScore W2017023812C2781413609 @default.
• W2017023812 hasConceptScore W2017023812C535046627 @default.
• W2017023812 hasConceptScore W2017023812C61943457 @default.
• W2017023812 hasConceptScore W2017023812C70905583 @default.
• W2017023812 hasConceptScore W2017023812C71924100 @default.

• next